Skip to main content
. 2021 Aug 31;11:702047. doi: 10.3389/fcimb.2021.702047

Figure 4.

Figure 4

Shannon alpha diversity plot comparing placebo- and rifaximin-treated study participants during each phase of the CHIM. Sample shape denotes samples from study participants who either developed campylobacteriosis (triangles) or did not (circles).